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Abstract: Degeneration of cardiac tissues is considered a major cause of mortality in the western world and is expected to 
be a greater problem in the forthcoming decades. Cardiac damage is associated with dysfunction and irreversible loss of 
cardiomyocytes. Stem cell therapy for ischemic heart failure is very promising approach in cardiovascular medicine. Ini-
tial trials have indicated the ability of cardiomyocytes to regenerate after myocardial injury. These preliminary trials aim 
to translate cardiac regeneration strategies into clinical practice. In spite of advances, current therapeutic strategies to 
ischemic heart failure remain very limited. Moreover, major obstacles still need to be solved before stem cell therapy can 
be fully applied. This review addresses the current state of research and experimental data regarding embryonic stem cells 
(ESCs), myoblast transplantation, histological and functional analysis of transplantation of co-cultured myoblasts and 
mesenchymal stem cells, as well as comparison between mononuclear and mesenchymal stem cells in a model of myocar-
dium infarction. We also discuss how research with stem cell transplantation could translate to improvement of cardiac 
function. 
Keywords: Heart, stem cells, transplantation, therapy. 
HUMAN EMBRYONIC STEM CELLS AS A SOURCE 
OF CARDIOMYOCYTES FOR CELL THERAPY AP-
PLICATIONS: OBSTACLES TO OVERCOME 
  In contrast to adult stem cells, embryonic stem cells 
(ESCs) have the potential to differentiate into tissue deriva-
tives of all three embryonic germ layers and therefore are 
termed pluripotent. Cardiomyocytes (CMCs) have been ob-
tained by all three types of murine embryo-derived stem 
cells: embryonic carcinoma (EC), embryonic stem (ES), and 
embryonic germ (EG) cells. In this chapter, we focus our 
attention on human ESCs (hESCs), due to their potential 
clinical application. hESC lines, isolated from the inner cell 
mass (ICM) of embryos can be propagated continuously in 
the undifferentiated state when grown on top of a mouse 
embryonic fibroblast (MEF) feeder layer. When removed 
from these conditions and grown in suspension, they begin to 
generate three-dimensional differentiating cell aggregates 
termed embryoid bodies (EBs). This in vitro differentiating 
system can be used to generate a plurality of tissue types. 
The ability of hESCs to differentiate into mature somatic 
cells was demonstrated using spontaneous and directed in 
vitro differentiation systems. So far, hESCs have been shown 
to differentiate into neuronal tissue [1], ß islet pancreatic   
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cells [2], hematopoietic progenitors [3], endothelial cells [4] 
and cardiac tissue [5,6].
 Interesting data were obtained by the 
use of adult stem cell for cardiac repair [7-9]. 
  Given the versatility of hESCs and the possibility of ob-
taining beating CMCs from them, (Fig. 1) [6,10] they appear 
as the main candidate for cell-based applications for cardiac 
repair. In fact, hESCs apparently fulfill most, if not all, the 
properties of an ideal donor cell line [11] (Table 1).  
  In the following sections, we will discuss briefly, but 
critically, the obstacles on the path to hESC-based cardiac 
therapy. A possible strategy for cell-replacement therapy 
would be to initially allow spontaneous differentiation of 
ESCs into multiple lineages in vitro followed by selective 
purification of the cardiomyogenic lineage isolated from 
embryoid bodies (Fig. 1). On this issue, Kehat et al.
 [5] show 
that transplanted hESC-derived CMCs substitute damaged 
pacemaker cells in a swine model of atrioventricular block, 
and are responsible for eliciting an ectopic rhythm compati-
ble with the animal’s survival. Their results provide compel-
ling evidence that this type of graft integrates electrome-
chanically within the recipient tissue, as discussed exten-
sively by Menaschè [12].  
  However, this is a relatively inefficient and haphazard 
process. We have to highlight that research on the exploita-
tion of hESCs for cell-replacement therapy is still in its in-
fancy, but the complex technical/technological problems are 202    Current Cardiology Reviews, 2011, Vol. 7, No. 3  Abdelwahid et al. 
well worth overcoming when contemplating the benefits that 
this procedure may bring. Promising data has been obtained 
so far; hESC-based cell therapy will revolutionize medicine 
in the near future, offering therapeutical alternatives for 
treatment of severe degenerative disorders. 
  In point of fact, several obstacles still remain unsolved:  
1)  The yield of CMC production has to be dramatically im-
proved. It is fundamental to work on the “ideal” culture 
conditions for CMCs differentiation. Unfortunately, the 
definition of strategies useful to the aim is not easy. The 
inherent differences between hESCs and their murine 
counterpart [5,12,13] necessitate the obligatory use of 
hESCs as a model; laws and ethical considerations place 
strong limitations to what can be done. A further compli-
cation is represented by differences between the various 
hESC lines [14-17]
 and their characterization which, to 
date, has been unsystematic. It appears that each hESC 
line possesses a unique expression signature and distinct 
cardiomyogenic inclination [18]. Hence, it is probably 
unrealistic to assume that an approach designed to im-
prove cardiac differentiation would be applicable to all 
hESC lines. Clearly, systematic characterization is neces-
sary to identify sub-categories of hESC lines. As under-
lined by Murdoch and co-workers [19], one possible so-
lution to this problem is the establishment of national or 
international hESC banks which would allow comparable 
and detailed characterization of deposited cells and pro-
vide scientists with all necessary information to choose 
the most suitable hESC line for their own research. 
2) Stimuli useful for directing hESC through the cardiac 
lineage are still only being investigated [20-23] A meth-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). hESC propagation and in vitro differentiation into CMCs. hESC lines can be propagated continuously in the undifferentiated state 
when grown on top of an MEF feeder layer. With the Kehat protocol‡ [5], when hESCs are removed from these conditions and grown in 
suspension, they begin to generate three-dimensional differentiating cell aggregates termed embryoid bodies (EBs). Two weeks after plating 
on gelatin coated plates, spontaneously contracting areas appear within the EBs. The Mummery protocol* [6], however, uses END-2 cells in 
the place of MEFs as feeders for hESCs; within 2 weeks, spontaneously contracting areas appear in the hESC-colonies. (hESCs: human Em-
bryonic Stem Cells; MEFs: Mouse Embryo Fibroblasts; EBs: Embryoid Bodies; END2: visceral endoderm-like cells; CMCs: cardiomyo-
cytes) Stem Cells and Heart Repair  Current Cardiology Reviews, 2011, Vol. 7, No. 3    203 
odic, combinatorial approach, using various stimuli 
(trans-stimuli, extra-cellular matrices, co-culture, physi-
cal stimuli etc) could be the best way of directing the dif-
ferentiation of stem cells in vitro in a cardiac stringent 
specific way. This speculation is supported by the fact 
that when in their natural milieu, cardiomyogenic differ-
entiation of stem cells probably involves multiple signal-
ing pathways. This may be mimicked in vitro with a 
combination of various methods that achieve a synergis-
tic effect. In fact, in vitro derived prevascularized scaf-
fold-free cardiac tissue patches from co-culture of car-
diomyocytes, endothelial cells and fibroblasts were found 
to greatly improve cell viability post transplantation [24].  
3)  Culture media. For clinical applications, it is imperative 
to develop well-defined and efficient in vitro protocols 
for cardiomyogenic differentiation of stem cells, that util-
ize chemically defined culture media supplemented with 
recombinant cytokines and growth factors. The main 
drawback of the actual xenosupport system is the risk of 
cross-transfer of animal pathogens that might hamper fu-
ture clinical applications. It was recently shown that non-
human sialic acid Neu5Gc, against which many humans 
have circulating antibodies, is incorporated into hES cells 
grown on mouse feeder layers [25]. The use of human 
plasma-derived serum [26] and development of a serum-
free support system [27] and animal-free feeder layer 
consisting of human fetal fibroblasts and adult epithelial 
cells [17] or foreskin cells
 [28] may provide an appropri-
ate solution to these risks. Nevertheless, in vitro up-
scaling of clinical grade cell products essentially free of 
xenogenic products in compliance with good manufactur-
ing practice (GMP) remains a significant hurdle [29]. 
Universal acceptable solutions to these challenges are 
needed to provide the stringent levels of safety and qual-
ity control that would make the clinical applications of 
stem cell transplantation therapy realizable. Hopefully, 
this will be achieved in the near future.  
4) Competency of derived CMCs in terms of excitation-
contraction coupling. Another important issue is to what 
extent these cells can be considered mature CMCs in 
terms of excitation-contraction coupling. Indeed, hetero-
genous electrophysiological properties have been demon-
strated in CMCs derived from separate differentiation 
methods within the same group [30]. This question can-
not be accurately answered at the moment since the dif-
ferentiation procedure has not been efficiently or even 
minimally standardized. However, some data [5] provide 
fairly convincing evidence that hESCs can integrate elec-
trically with the recipient myocardium, suggesting that 
they are capable of contributing to the augmentation of 
pump function following injury.  
5) Immune rejection has to be blocked. Upon differentia-
tion, ES cells express molecules of the major 
histocompatibility complex (MHC), in particular MHC I, 
while MHC II expression levels are low or absent [31]. 
Thus, decreasing the expression of MHC I by genetic 
modification could improve immunologic tolerance. 
Alternatively, minimal but targeted conditioning of CD4 
and CD8 T-cells may be an option to promote tolerance 
of embryonic stem cell-derived tissues [32].  
  On this issue, recent high-profile reports of the derivation 
of human embryonic stem cells from human blastocysts pro-
duced by somatic cell nuclear transfer (SCNT) [1,33,34] 
have highlighted the possibility of making autologous cell 
lines specific to individual patients. Given the range of im-
munophenotypes of hESC lines currently available, rejection 
of the differentiated cells by the host is a potentially serious 
problem. SCNT offers a means of circumventing this by 
producing embryonic stem cells of the same genotype as the 
donor. However, this technique is not without problems 
since it requires resetting of the gene expression program of 
a somatic cell to a state consistent with embryonic develop-
ment [35]. 
  Currently, the use of SCNT is under investigation from 
several points of view (ethical, scientific, techni-
cal/technological) and has a promising potential for treat-
ment of a variety of degenerative diseases. Furthermore, with 
the advent of other techniques such as xeno-free [36,37] and 
direct differentiation of resident cells to cardiomyoyctes [38] 
may offer additional and exciting avenues for autologous cell 
therapy in the future. 
6)  Tumorigenicity may be a problem, even when terminally 
differentiated CMCs are used for cell replacement. Im-
plantation of undifferentiated ES cells leads to the forma-
tion of benign teratomas in the recipients [34,35,39,40]  
Table 1.  hESCs Meeting the Need for Cell-based Applications for Cardiac Repair (hESC:human Embryonic Stem Cell; CMC 
Cardiomyocytes; MHC:Major Histocompatibility Complex) 
 
 
 204    Current Cardiology Reviews, 2011, Vol. 7, No. 3  Abdelwahid et al. 
  As discussed by Authors [41,42], an ES-derived teratoma 
is not in essence malignant, but its natural propensity to 
grow makes it potentially dangerous when implanted into an 
individual and, as such, a crippling obstacle on the path to 
ES cell therapeutics. Recent experiments suggest that forma-
tion of a teratoma may be dependent upon experimental con-
ditions. Bjorklund et al. [43] have, for instance, shown that 
teratoma formation could be prevented in a majority of cases 
when pre-differentiated mouse ES cells were implanted into 
the rat brain at a very low density. Asano et al. [44] showed 
that ES cells implanted allogenically into a non-human pri-
mate fetus in utero formed a teratoma when developing in a 
natural cavity, but conversely integrated normally in tissues 
when implanted within various organs. Teratoma formation 
does not appear, therefore, as an unavoidable consequence of 
ES cell implantation but rather as a phenomenon, the mecha-
nisms of which require further investigation in order to iden-
tify the safest procedures for clinical application. Tumori-
genicity demands the use of an extensively characterized, 
pure, differentiated cell population. Negative selection of 
Oct4 (undifferentiation marker) expressing cells might be a 
solution. New strategies and methodologies need to be de-
veloped to isolate the terminally differentiated cells. ES cell 
implants can be tagged with some kind of death signal in 
such a way that when they start to form tumors, or cause 
severe complications, they can be cleared from the body, 
leaving the host unaffected. Other safeguards proposed to 
purify cardiomyocytes such as flow cytometry cell sorting 
using cardiomyocyte-specific fluorescent dye [45] or cardiac 
plasma membrane surface marker [46] and other strategies 
reviewed elsewhere [47] would further enhance the safety 
profile of these exogenously derived cardiomyocytes. As yet, 
there is no validated solution to this problem.  
CO-TRANSPLANTATION IN REPAIRING MYO-
CARDIAL DAMAGE 
  Most studies with cell transplantation have been per-
formed in animal models and patients with ischemic cardio-
myopathy. Although results are promising, the most appro-
priate cell for this therapy is still a matter of discussion. 
Skeletal myoblasts transplantation has been shown effective 
in experimental
  [48-52] and clinical
  [53,54] studies. They 
differentiate into viable muscle fibers within the scared tis-
sue but they lack morphological differentiation into cardio-
myocytes and no intercalated discs develop between trans-
planted cells and the native adult cardiomyocytes. On the 
other hand, adult stem cells are pluripotent [55], but some 
studies suggested of only an angiogenic potential [56]. In the 
same model of ischemic cardiomyopathy, but comparing the 
effects between both cells separately we found that skeletal 
myoblasts transplantation resulted in myogenesis and im-
provement of ventricular function. In contrast, treatment 
with mesenchymal stem cells resulted in neoangiogenesis 
and no functional effect [57].
 
 Manasché  et al [58] demonstrated in a phase I clinical 
trial that skeletal myoblasts alone are able to improve ven-
tricular function but with a high incidence of ventricular ar-
rhythmias. One of the possible explanations is that when 
only new muscular fibres are provided (myoblast transplan-
tation) these structures can become ischemic by the lack of 
vascularization and thus the tissue become more prone to 
arrhythmias. As some authors suggest that bone marrow 
stem cells have only an angiogenic potential
 [57] in a fibro-
sis, we have hypothesized that some problems could be 
eliminated providing contractile and angiogenic cells. The 
option for combined trasplantation of skeletal myoblasts and 
mesenchymal stem cells was based on pathophysiology of 
ischemic cardiomyopathy, characterized by chronic fibrosis 
and no vascularization of this region. This is the rationale for 
our studies with myoblasts and mesenchymal cells combined 
to get angiomuscular regeneration. 
  We performed one study [59]
 in a model of myocardial 
infarction that observed increased ejection fraction after 30 
days of both cells transplantation (myoblast and mesenchy-
mal stem cells together) (24.03±8.68% to 31.77±9.06% 
p=0.011) and the difference was significant when this group 
was compared to control group at the same time. 
(31.77±9.06% vs 23.54±6.51% p=0.020) (Fig. 2). Histologi-
cal evaluation was made by Gomori’s Trichrome and identi-
fied cells with morphological characteristics of skeletal mus-
cular fibers that colonize the region of fibrosis. The forma-
tion of new blood vessels was also identified in this region 
however, the presence of neither muscle nor blood vessels 
was visualized in the region of myocardial fibrosis in control 
group (Fig. 3). 
 
 
 
 
 
 
 
 
 
Fig. (2). Ejection Fraction(EF%) of left ventricle between two 
groups and in the two periods of evaluation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). New skeletal fibers (white arrows) and new vessels and 
endothelial cells (black arrows) identified in a myocardial infarction 
(MI) (Gomery’s Trichrome, x 200). Stem Cells and Heart Repair  Current Cardiology Reviews, 2011, Vol. 7, No. 3    205 
  Whether these same effects can be seen in other cardio-
myopathies is still not known, so we performed one study on 
model of Chagasic cardiomyopathy [60]. We emphasize that 
in both described studies: Chagasic cardiomyopathy and 
myocardial infarction the co-transplantations included both 
cellular types co-cultured to allow in vitro interaction as re-
ported previously [61].
 The option for combined transplanta-
tion of skeletal myoblasts and mesenchymal bone marrow 
cells was based on pathophysiology of chagasic cardiomy-
opathy, characterized by chronic inflammation, sites of fi-
brosis and subendocardial ischemia. Cell transplantation in 
Chagasic model increased ejection fraction, reduced left ven-
tricle volumes, both end systolic and diastolic (Table 2). His-
tological evaluation was made by hematoxylin eosin and 
identified cells with morphological characteristics of skeletal 
muscular fibers that colonize the injured myocardium (Fig. 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). New skeletal fibers(white arrows) identified in an injured 
myocardium (IM) of Chagas disease. (H&E, X200). 
 
  This effect on ventricular remodelling seems to be more 
related to the pathology and the way cells are transplanted 
into the heart than to the transplanted cell. Nevertheless, 
transplantation of co-cultured myoblasts and mesenchymal 
stem cells to a rat model of post-infarction ventricular dys-
function didn’t prevent ventricular remodelling despite of 
improvement in ventricular function [59]. Cells were in-
jected only in anterior wall, differently from the current 
model where cells were injected in a more diffuse area (ante-
rior and lateral wall). Further studies are necessary to evalu-
ate whether the effect on ventricular remodelling is depend-
ent on the model of cardiomyopathy and the way cells are 
deployed. 
FUNCTIONAL COMPARISON BETWEEN MONO-
NUCLEAR AND MESENCHYMAL STEM CELLS IN 
A MODEL OF MYOCARDIUM INFARCTION  
  Experimental studies suggest that cardiac bone marrow 
stem cells (SC) transplantation can has a favorable impact on 
tissue perfusion. The strategy to repair the myocardial scar 
after infarction with SC has been proposed based on its ca-
pacity to differentiate according to the environment and 
could give a new perspective for myocardial regeneration 
[62][55,62-64]. Studies in human beings have shown im-
provement in clinical and functional cardiac status explained 
mainly by the angiogenic potential after stem cells transplan-
tation [65-67]. Bone marrow stems cells are composed by 
mononuclear stem cells (MoSC) that contain hematopoietic 
stem cells with precursors of endothelial cells and mesen-
chymal stem cells (MeSC). MeSC shows pluripotentiality for 
mesoderm-derived cells, but it is only 0,01- 0,05% of MoSC 
although they can be enriched based on the adhesion capac-
ity of MeSC on tissue culture plate [67]. To compare the 
functional outcome of mononuclear stem cells (MoSC) and 
mesenchymal stem cell (MeSC) therapy after myocardial 
infarction in rats, we used several approaches. The flow cy-
tometric analysis we used was CD45+ and CD 34+ for the 
MoSC and CD45- and CD34- for the MeSC. The MeSC was 
positive for vimentin in vitro. There was difference in base-
line LVEF and LVEDV between all groups. After one 
month, LVEF decreased in the control group and remained 
unchanged in MoSC and MeSC groups. The myocardium 
was remodeled in all of the groups (Tables 3 and 4). Thus 
functional effectiveness was not demonstrated with both cell 
type therapy: MoSC and MeSC, when LVEF was analyzed 
Table 2.  Functional Evaluation of Cells Transplantation in a Model of Chagas Disease 
Group  Control  Co-culture  Difference Between Groups (p) 
LVEDV. ml pre  0.69 ± 0.11  0.82 ± 0.07   
LVEDV. ml post  0.73 ± 0.14  0.65 ± 0.14  0.0166 
P 0.6311  0.0004   
LVESV. ml pre  0.44 ± 0.08  0.56 ± 0.05   
LVESV. ml post  0.46 ± 0.12  0.32 ± 0.09  0.0001 
P 0.6523  <0.0001   
EF% pre  36.74 ± 3.63  30.10 ± 5.71   
EF% post  37.42 ± 6.66  51.76 ± 6.63  <0.0001 
P 0.7684  <0.0001   206    Current Cardiology Reviews, 2011, Vol. 7, No. 3  Abdelwahid et al. 
by echocardiogram in this post-infarction dysfunctional 
model. Although we observed the stabilization of the MeSC 
therapy and no effects have been demonstrated to affect the 
ventricular dilatation. In spite of the fact that there was no 
improvement of the functional effects, the potential myocar-
dial perfusion may warrant further analysis [68]. 
HISTOPATHOLOGICAL COMPARISON BETWEEN 
MONONUCLEAR AND MESENCHYMAL STEM 
CELLS IN A MYOCARDIAL INFARCTION MODEL 
  The histopathological analysis demonstrated new vessels 
in both cell type therapy, but with morphological differences. 
The new vessel formed in the scar after MoSC transplant is 
constituted of endothelial cells and lumen (Fig. 5), while in 
the new vessels formed after the MeSC transplant (Fig. 6), 
there was also the presence of smooth muscle. The latter was 
demonstrated by the presence of muscle in new vessel 
stained by anti-desmin with immunoflurescence in the myo-
cardial scar. The control demonstrated only the scar with 
collagen deposit: fibrosis. This new vessel resulted from 
MeSC transplantation could have more physiological poten-
tial for vasomotor response, but the potential effect on myo-
cardial perfusion may have great significance in cardiac re-
covery. Thus both cell type therapies: MoSC and MeSC have 
angiogenic capacity. The new vessel formed by MeSC trans-
plant from the histopathological point of view, was complete 
and characterized for the presence of smooth muscle with 
endothelial cells and lumen [69]. Additional paracrine effects 
of stem and progenitor cells in cardiac repair has been exten-
sively reviewed [70].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Angiogenesis: Multiple new vessels after MoSC therapy in 
the myocardial scar stained by Gomori's Trichrome (x 200). 
CLINICAL USE OF MYOBLAST TRANSPLANTA-
TION: RATIONALE  
  Congestive heart failure caused by myocardial infarction 
continues to be a major clinical problem despite recent 
therapeutic advances. Formation of a fibrotic scar that re-
places viable myocardium leads to decreased systolic func-
tion, left ventricular remodeling, aneurysm formation and 
subsequently to the progression of congestive heart failure. 
Unfortunately, cardiac transplantation may be an option only 
in selected end-stage heart failure patients, mainly due to   
 
 
 
Table 3.  Baseline and After 1-month LVEF  
Control (n=21)  MeSC (n=13)  MoSC (n=8) 
Variable 
Mean ± SD  Mean ± SD  Mean ± SD 
p* 
LVEF baseline  26.84±7.05 26.62±7.34 21.79±8.77 0.2505 
LVEF 1-month  22.32±6.94 25.55±10.21 18.60±6.11 0.2980 
p
 0.0045  0.6505  0.4232   
(*) ANOVA (**) Adjusted to baseline (
) Paired t test (p<0.05) 
LVEF (Left Ventricular Ejection Fraction).  
 
Table 4.  Differences Between Baseline and 1-month 
Control (n=21)  BMSC (n=13)  Mononuclear (n=8) 
Variable (1month-baseline) 
Mean ± SD  Mean ± SD  Mean ± SD 
p 
LVEDV 0.13±0.16 0.16±0.06 0.39±0.16 0.0025** 
LVESV 0.13±0.13 0.13±0.09 0.34±0.13 0.0004* 
LVEF -4.53±6.48 -1.07±8.30 -3.19±10.61 0.4733* 
(*) ANOVA (**) Kruskal-Wallis (p<0.05) 
LVEDV (Left Ventricular End Diastolic Volume), LVESV (Left Ventricular End Systolic Volume) and LVEF (Left Ventricular Ejection Fraction). Stem Cells and Heart Repair  Current Cardiology Reviews, 2011, Vol. 7, No. 3    207 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). New vessel after MeSC in the myocardial scar stained by 
Gomori's Trichrome (x 400). 
 
organ shortage. Restoration of the total amount of contractile 
cells within the necrotic tissue as a result of cell transplanta-
tion into myocardium have been widely studied in both ex-
perimental and clinical conditions [71] Among variety of cell 
studied, autologous skeletal myoblasts, chronologically the 
first to enter the clinical arena, are one of the most encourag-
ing cell source for cardiac repair because of their biologic 
properties and lack of ethical and immunological issues (Figs 
7-9). Transplantation of totipotent stem cell types, including 
bone marrow derived stem cells, into a fibrous postinfarction 
scar may result in their differentiation into fibroblasts [71-
73], therefore direct myocyte precursors, myoblasts, have 
been considered as possible cell sources in patients with 
chronic, postinfarction myocardial injury. 
  Numerous studies have explored different delivery tech-
niques. As skeletal myoblasts do not extravasate, their poten-
tial application in myocardial regeneration requires direct 
cell injection into the area of damaged myocardium. There-
fore surgical approach (open-chest surgery) and several 
catheter-based methods had been proposed.  
MYOBLAST TRANSPLANTATION DURING CAR-
DIAC SURGERY 
  The initial clinical experience with autologous skeletal 
myoblast transplantation during open chest cardiac surgery 
was obtained by Ph. Menasché et.al., followed by phase one 
clinical trials performed both in Paris and in Poznan 
[58,74,75]. Both trials were done in patients in whom direct 
intramyocardial injections could be performed during coro-
nary artery by-pass grafting (CABG). In the first clinical 
case described [58] several injections of the cell suspension 
into area of postinfarction injury within inferior wall of the 
left ventricle were performed. Five months after the proce-
dure, a significant clinical status improvement was observed, 
including decrease of symptoms of heart failure by one 
NYHA class, an increase in segmental contractility and ejec-
tion fraction seen on echocardiography as well as increase in 
tracer activity on positron emission tomography suggesting 
new onset metabolic activity in the previously non viable 
scar area [58]. An independent phase one clinical trial on 
autologous skeletal myoblast transplantation in patients un-
dergoing CABG [71,74,75] was performed in Poznan. MI 
survivors scheduled for CABG, with an akinetic area of the 
left ventricle and no viable myocardium was detected by 
means of dobutamine stress echocardiography were included 
into the study. A skeletal myocardial biopsy was obtained in 
all patients from the vastus lateralis. The biopsy sample was 
digested and myoblasts (satellite cells) were isolated. The 
cells were cultured for three weeks to increase the number of 
cells to be implanted. A measurable increase in segmental 
contractility was seen in all patients 2 to 3 months after the 
procedure and this effect was maintained throughout a 36-
months follow-up period. However, 3 years after combined 
myoblast transplantation and CABG, in almost every third 
case in the Poznan series, end diastolic left ventricular di-
ameter increased, suggesting that cell transplantation did not 
prevented left ventricular remodeling or the number of cells 
transplanted was not sufficient to prevent left ventricular 
dilatation. 
  A US-based multicenter phase one clinical trial aimed at 
evaluation of myoblast transplantation during CABG has 
also been reported [76]. Eleven patients underwent myoblast  
 
 
 
 
 
Fig. (7). Procedural steps of cell transplantation using trans-coronary venous approach. Left: coronary artery visualization in LAO 30 view; 
middle: administration of the contrast medium via a guiding catheter placed in the coronary sinus in LAO 30 view, note the balloon inflated 
at the tip of the guiding catheter to slow the contrast medium outflow; right: placement of TransAccess® catheter system in the anterior in-
terventricular vein and injection of the cell suspension via the IntraLume® microcatheter into anterior wall myocardium – the arrow indicates 
the microcatheter tip. 
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Fig. (9). Intravascular ultrasound image obtained from the cardiac 
venous site. Please note the visibility of the pericardium (big ar-
rows) and the coronary artery parallel to the vein (small arrows), 
enabling the orientation of TransAccess® catheter system. 
 
transplantation combined with CABG. Echocardiography, 
PET and MRI scans showed evidence of increased viability 
in the area of grafted scar. Improvement of the mean ejection 
fraction from 22.7% to 35.9% has been observed. Another 
phase one study evaluating myoblast injections during 
CABG has been reported by Herreros et al. [77], suggesting 
safety and feasibility of the method as well as indicating its 
possible efficacy in increasing contractile left ventricular 
performance. 
  Cell transplantations during cardiac surgery has certain 
advantages, including easy access and good visualization of 
the target site as well as possible delivery of big amount of 
cells per unit area. However, direct transepicardial approach 
may cause additional risk related to the surgery. It must be 
underlined that possible candidates for cell transplantation 
usually have a history of multiple infarctions, with signifi-
cant LV dysfunction and clinical symptoms of severe heart 
failure, being high-risk candidates for open-chest surgery. 
Furthermore open-chest approach does not give free access 
to septal wall which is frequently inflicted by postinfarction 
injury.  
  Clear interpretation of clinical data obtained from trials 
evaluating cell transplantation during CABG is not possible. 
The effect of CABG and cellular transplantation performed 
at the same time cannot be easily distinguished. Despite the 
use of careful inclusion criteria aimed at selection of patients 
with no viable myocardium within the target postinfarction 
area, the possible effect of skeletal myoblast transplantation 
may be enhanced by myocardial revascularization. Large on-
going and future clinical trials evaluating efficacy of 
myoblast injections during CABG may allow evaluating of 
the cell effect independently on restoration of blood flow. 
Nevertheless, a recently concluded randomized, placebo-
controlled study of 97 patients, the myoblast autologous 
grafting in ischemic cardiomyopahty (MAGIC) trial failed to 
show improved LV function at 6 months after myoblast 
transplantation [78].  
PERCUTANEOUS MYOBLAST TRANSPLANTATION 
  Myoblast transplantations, performed as a sole therapy 
during percutaneous procedures, may allow the evaluation of 
the cellular effect independent of revascularization. In addi-
tion, it may enable repeated injections in patients with severe 
myocardial injury, since excessive numbers of transplanted 
cells in a single injection may result in a small percentage of 
survived and grafted cells. Initial experience has been ob-
tained with cell injection into myocardium with the use of 
both endoventricular catheter systems [79] and transvenous 
approach [80,81].  
  The efficacy of cell transplantation may be very much 
dependent on the design of catheter system used [82,83]. 
Currently available endoventricular catheter systems, utilized 
for intramyocardial injections of therapeutic agents, have 
limited stability, since the injection pressure can cause ex-
pulsion of the needle tip from the injection site. After needle 
withdrawal from a short perpendicular injection channel, 
therapeutic agent leakage back to the ventricle may occur. 
Such a back-flush of cells from the puncture site may cause 
the presence of graft cells in the systemic circulation and/or 
diminished number of cell delivered to the target area. 
Moreover, for endoventricular systems in which needle is 
directed perpendicularly to the inner surface of cardiac mus-
 
 
 
 
 
Fig. (8). Procedural steps of cell transplantation using trans-coronary venous approach. Left: coronary artery visualization in LAO 30 view; 
middle: administration of the contrast medium via a non-occlusive guiding catheter placed in the coronary sinus; right: placement of 
TransAccess® catheter system in the anterior interventricular vein and injection of the cell suspension via the IntraLume® microcatheter into 
the septum – the arrow indicates the microcatheter tip. Stem Cells and Heart Repair  Current Cardiology Reviews, 2011, Vol. 7, No. 3    209 
cle wall and does not follow the heart movement, thinned 
postinfarction scar is currently a relative contraindication.  
  Another catheter-based endovascular system for direct 
myocardial injection using IVUS guided needle punctures 
via the coronary venous system (the TransAccess®, Trans 
Vascular, Manlo Park, CA) has been recently developed 
[84,85]. The TransAccess® catheter is a monorail, compos-
ite catheter system combining both a phased-array IVUS and 
a pre-shaped adjustable nitinol needle. After placing the 
TransAccess® system in the target coronary vein, through 
the coronary sinus, the system is oriented using the corre-
sponding artery, pericardium and ventricular myocardium as 
landmarks with IVUS imaging. The nitinol needle is then 
extended into the myocardium and a microinfusion catheter 
(IntraLume™, TransVascular Inc.) is then advanced through 
the needle deep into the myocardium with simultaneous in-
jection of the therapeutic agent.  
  The POZNAN trial [81] was performed as a phase one 
clinical trial for both the TransAccess® catheter system and 
for percutaneous autologous myoblast transplantations per-
formed as a sole therapy. The trial has confirmed the feasi-
bility of intramyocardial injections performed using the 
TransAccess® system. Precise advancement of the micro 
lumen catheter in the remote target area up to 4 cm deep 
within the injured myocardium was obtained. The use of 
both the anterior interventricular vein as well as the middle 
cardiac vein, parallel to the posterior descending coronary 
artery, has been shown to be feasible. In the POZNAN trial, 
in 4 cases the middle vein was used to advance the TransAc-
cess® system closer to the apical segments of the left ventri-
cle, as compared to cases using the anterior interventricular 
venous approach [81]. The lack of procedural success in one 
patient, related to the inability of appropriate positioning of 
the guiding catheter across the venous valve present at the 
bifurcation of the great cardiac vein, suggests the need for 
better coronary sinus guiding catheter design (10F guiding 
catheters were used). In remaining POZNAN trial patients, 
two to four intramyocardial injections 1.5-4.5 cm deep were 
performed in each patient, delivering up to 100 million cells 
in 0.6 – 2.5 ml of saline. During 6 months follow-up NYHA 
class improved in all patients and ejection fraction assessed 
by echocardiography increased 3-8 percent in 6 out of 9 
cases [81,83].  
 Smits  et al. [79] used transventricular approach to inject 
myoblast suspensions into the area of postinfarction injury. 
They observed increase in LV ejection fraction assessed by 
angiography at 3 month follow-up, but nucluear radiography 
and magnetic resonance failed to confirm this improvement. 
However, they recently published a very interesting study 
[86] have shown hemodynamic improvement evaluated by 
pressure-volume loops after follow-up for up to one year 
after percutaneous myoblast transplantation. 10-15 injections 
of autologous myoblasts using Myostar™ (Cordis, Warren, 
NJ) resulted in increased ejection fraction at 6 months, in-
creased cardiac output, reduction of end-systolic volume and 
a trend towards improved stroke work. Another recently 
published study [86] decribes results of transventricular in-
jections performed using fluoroscopy guided MyoCath™ 
catheter (Bioheart, Weston, FL) or the NOGA™-guided 
catheter system (Biosense-Webster, Waterloo, Belgium). 
The study failed to show improvement in the ejection frac-
tion but wall motion score index improved both at rest at 
under low-dose dobutamine. In addition, the result of the 
study indicate the possibility of arrhythmogenic effect of 
myoblast transplantation. 
MYOBLAST-RELATED SAFETY ISSUES 
  Myocardial and skeletal muscle tissues differ signifi-
cantly in their electromechanical properties. Cardiac cells, 
having special cell-cell junctions, even though separated one 
from another, act together synchronically. Junctions contain 
adherins and gap junctions for mechanical and electrical 
coupling. Cardiac tissue gap junctions contain connexin-43 
transmembrane protein by which electrical current can be 
fast and freely conducted [3]. Although certain data suggest 
that skeletal myoblasts may acquire few characteristics of 
cardiomyocytes, generally it could be assumed that the 
grafted cells do not transdifferentiate and keep morphologi-
cal and electrophysiological properties of skeletal muscle 
[87,88]. It is speculated that skeletal myoblasts (satellite 
cells) are not able to form intercellular junctions characteris-
tic for cardiomyocytes. However, it was shown that the lack 
of junctions between grafted cells and host tissue do not pre-
clude improvement in LV contractile function [87].
 
  There is evidence that this positive effect of skeletal 
myoblasts on myocardial contractility seems to last over time 
and is correlated with the number of implanted cells [50].
 
Experimental studies performed on myocardial wound strips 
indicate that skeletal myoblast grafts do contract when ex-
ogenously stimulated [49]. In addition, cardiomyocytes and 
skeletal myoblasts, when placed in co-culture, forms syn-
chronous beating network [89]. It has been suggested that 
transplanted cells can contract synchronously even in the 
absence of connections between cells, because a simple 
stretch may initiate contraction [90]. This phenomenon is 
important due to the possibility of insulation of transplanted 
cells by scar tissue. The scar may form a physical barrier 
which impede electromechanical coupling.  
  It is speculated that the inability of skeletal myoblasts to 
transdifferentiate to cardiomyocytes and to form junctions 
with neighboring cells may be a substrate for ventricular re-
entry arrhythmia. Indeed, current experimental and clinical 
data suggest a possibility of increased risk of arrhyth-
mogenicity. In their first clinical series, Menasché at al. [58] 
implanted automatic internal cardioverter-defibrillators 
(AICD) in 4 out of 10 patients receiving autologous skeletal 
myoblast transplantations during CABG due to sustained 
episodes of ventricular tachycardia (VT). The possible ar-
rhythmogenic effect have been also noticed in an endoven-
tricular catheter-based trial which had to be temporarily 
stopped because of 2 sudden deaths, probably due to ar-
rhythmia. In the Poznan CABG phase one experience 
[74,75], episodes of sustained ventricular tachycardia (VT) 
were observed in first 2 patients during early postoperative 
period, but prophylactic amiodarone administration in other 
patients prevented VT episodes and no amiodarone treatment 
was continued later then 6 weeks during follow-up. This 
corresponds to the experience of Menasche et al [58] Later 
during follow-up period only one of their four AICD patients 
experienced asymptomatic VT episodes [71]. On the other 210    Current Cardiology Reviews, 2011, Vol. 7, No. 3  Abdelwahid et al. 
hand, observations from percutaneous series in the POZNAN 
trial, indicating successful prevention of cell transplantation-
related ventricular arrhythmia by prophylactic amiodarone 
administration, suggest that AICD implantations may not 
necessarily needed in all patients that undergo myoblast 
transplantations [81,83].  
  Based on published data from clinical studies, it could be 
speculated that the possible arrhythmogenic effect of 
myoblast transplantation is noticed only in the initial weeks 
after the procedure. The possible arrhythmogenic effect of 
myoblast transplantation is more probably related to its me-
chanics, including myocardial puncture and the inflamma-
tory response to transplanted cells, some of which die after 
injection, than to possible problems with electromechanical 
coupling between newly developed myocytes and cardio-
myocytes. Possible electromechanical coupling problems 
would result in late arrhythmia as cells differentiate (down-
regulation of connexin-43 and N-cadherin), a situation that 
has not been observed in clinical trials so far.  
  At the current stage, only moderate numbers of patients 
that have undergone autologous skeletal myoblast transplan-
tations, it is difficult to predict whether skeletal myoblasts 
are really arrhythmogenic, especially that patients with 
ischemic LV dysfunction frequently develop ventricular ar-
rhythmia. Indeed, the experience of MAGIC trial [78] re-
flected this trend whereby no significant difference in ven-
tricular arrhythmias or major cardiac adverse events was 
detected between myoblast-treated patients and placebo con-
trol group at 6-month follow-up. Nevertheless, future studies 
on cell transplantation in patients with postinfarction heart 
failure will have to focus on potential arrhythmogenic effect. 
Similarly, large phase two/three clinical trials are needed to 
assess the efficacy of myoblast transplantation in chronic 
postinfarction myocardial injury. 
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